Celltrion and Formycon with Fresenius Kabi launched their respective ustekinumab biosimilars (Steqeyma and Otulfi), joining 4 ...

The FDA had approved Otulfi in September 2024 to treat Crohn’s disease, ulcerative colitis, psoriasis and active psoriatic arthritis. Information on pricing is not yet available.

Otulfi ® is an ustekinumab biosimilar for the reference product Stelara ® (ustekinumab ... dose prefilled syringe for ...

Biocon Biologics, one of India's leading biologic drug manufacturers, announced on Friday the results of a Phase-3 study on a ...

It encompasses all indications approved for the STELARA® reference product ... solution in a single-dose vial. Plaque Psoriasis (PsO) in adults and pediatric patients 6 years of age and older ...

YESINTEK will be available in all the same formulations currently provided by Stelara. The available presentations are 45 mg/0.5 mL PFS, 90 mg/mL PFS, 45 mg/0.5 mL vial, and 130 mg/26 mL vial.

Selarsdi (ustekinumab-aekn; Teva and Alvotech), and Yesintek (ustekinumab-kfce; Biocon Biologics), all biosimilars to Stelara (ustekinumab; Johnson & Johnson) are now available in the US.

FYB202/Otulfi ® (ustekinumab-aauz), a biosimilar to Stelara®, launched in the United States and the European Union FYB202/Otulfi ® is now commercially available in both subcutaneous and intravenous ...

It encompasses all indications approved for the STELARA® reference product ... The intravenous infusion is provided as a 130mg/26 mL (5mg/mL) solution in a single-dose vial. Plaque Psoriasis ...

Celltrion today announced the U.S. launch of STEQEYMA��(ustekinumab-stba), a biosimilar to STELARA� (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024.